Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

Indapta is sidestepping genome engineering for its universal NK cells, a strategy that not only reduces manufacturing costs but also broadens the number of cancer patients it could treat relative to genetically edited allogeneic NK cell therapies.

Indapta Therapeutics Inc. was founded in 2017 based on IP covering the use of unedited FCER1G-deficient NK, or “G-NK,” cells plus at least one antitumor antibody recognized by CD16 to kill cancer cells. Indapta licensed the IP from Michigan State University, where co-founder Sungjin Kim was an assistant professor. Kim is now an associate professor of medical microbiology and immunology at University of California Davis...